ADPT vs JPM · rev $142.4M vs P/E 14, rev $57.35B
Adaptive Biotechnologies Corp (ADPT) versus JPMorgan Chase & Co (JPM) — a side-by-side from cached financials, not a winner call.
Adaptive Biotechnologies Corp (ADPT) is a diagnostics & research company listed on NASDAQ.
JPMorgan Chase & Co (JPM) is a banks - diversified company listed on US. It is led by Jamie Dimon.
Latest reported ADPT revenue for 2026-06-30 was $142.4M. Net income was -$59.8M. ADPT currently screens at market cap $2.69B.
Latest reported JPM revenue for 2026-06-30 was $57.35B. Net income was $21.16B. Revenue was up 15.1% from 2026-03-31 to 2026-06-30. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
ADPT currently screens at market cap $2.69B. JPM currently screens at market cap $805.69B and trailing P/E 14.2.
Not investment advice. Open the ADPT and JPM stock pages for the full models.
Not investment advice.